Kiniksa Pharmaceuticals
KNSA
102 hedge funds and large institutions have $402M invested in Kiniksa Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 17 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
1.7% less ownership
Funds ownership: 90.98% → 89.28% (-1.7%)
2% less funds holding
Funds holding: 104 → 102 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
25% less capital invested
Capital invested by funds: $537M → $402M (-$135M)
34% less call options, than puts
Call options by funds: $2.87M | Put options by funds: $4.33M
Top Buyers
Top Sellers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$25.4M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$24.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.07M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.58M |
KNSA Hedge Fund Activity: Q2 2021 in Review
102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2021, worth a combined $402M — down 25% from $537M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of KNSA and 15 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 37 added.
The largest buyer was State Street, adding an estimated $13.4M. The largest seller was Ameriprise, exiting entirely with an estimated $25.4M sold.
- 102 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2021, down from 104 in Q1 2021.
- Funds reported $402M of Kiniksa Pharmaceuticals stock for Q2 2021, down 25% quarter-over-quarter.
- 15 funds opened new Kiniksa Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of -2 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2021 was State Street, an estimated $13.4M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2021 was Ameriprise, an estimated $25.4M sold.
Based on aggregated 13F filings for Q2 2021.